Summary of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings as of Dec 8, 2018

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Corporate Logo
During 2018 Q2 the big money sentiment decreased to 1.3. That’s change of 0.53, from 2018Q1’s 1.83. 24 investors sold all, 45 reduced holdings as Amicus Therapeutics, Inc. ratio is negative. 61 grew positions while 29 funds bought positions. Funds hold 216.23 million shares thus 0.98% more from 2018Q1’s 214.13 million shares.
Teacher Retirement Of Texas invested in 0% or 37,696 shs. State Board Of Administration Of Florida Retirement System invested in 83,158 shs. Sabby Mngmt Limited Co invested 0.09% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Zurcher Kantonalbank (Zurich Cantonalbank) reported 11,925 shs or 0% of all its holdings. Moreover, Raymond James & Associates has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Bank & Trust Of America De owns 680,464 shs for 0% of their capital. Moreover, Venbio Select Advisor Limited Company has 5.63% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 9.37M shs. Sei Investments has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 34,142 shs. 132,400 were accumulated by Quantitative Invest Management Ltd Company. Eagle Asset Management has invested 0.21% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). State Street owns 7.96M shs for 0.01% of their capital. Aqr Capital Management Ltd Company holds 0% or 225,418 shs. Gradient Invests Limited Liability Corp invested in 0% or 4,000 shs. Glenmede Na owns 549 shs.

Amicus Therapeutics, Inc. had 3 sales and 4 insider buys since July 2, 2018. This’s net activity of $8.07 million. $78,166 worth of stock was sold by Andrews Kurt J. on Monday, July 2. PERCEPTIVE ADVISORS LLC bought $1.17M worth of stock or 100,000 shs.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

A total of 2 analysts rate Amicus Therapeutics (NASDAQ:FOLD) as follows: 0 “Buy”, 2 “Hold” and 0 “Sell”. Ğ¢herefore 0 are bullish. (NASDAQ:FOLD) has 2 ratings reports on Dec 8, 2018 according to StockzIntelligence. The stock rating was downgraded by Chardan Capital Markets to “Neutral” on Friday, August 17. Listed here are Amicus Therapeutics, Inc. (NASDAQ:FOLD) PTs and latest ratings.

29/10/2018 Broker: Citigroup Rating: Neutral New Target: $12 Initiates Coverage On
17/08/2018 Broker: Chardan Capital Markets Old Rating: Buy New Rating: Neutral Old Target: $18.5 New Target: $15 Downgrade

FOLD is touching $9.92 during the last trading session, after decreased 4.25%.Amicus Therapeutics, Inc. has volume of 2.45M shares. Since December 8, 2017 FOLD has declined 10.62% and is downtrending. FOLD underperformed by 26.24% the S&P 500.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases.The firm is valued at $1.88 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies.Last it reported negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

For more Amicus Therapeutics, Inc. (NASDAQ:FOLD) news brought out recently go to:,,, or The titles are as follows: “WhatsApp hires Ezetap’s Bose to be its India head – Nasdaq” brought out on November 21, 2018, “‘Crypto hangover’ hammers Nvidia’s outlook, shares drop 17 pct – Nasdaq” on November 15, 2018, “Slow train to China: India’s trade ties with Beijing taking time to ripen – Nasdaq” with a publish date: December 06, 2018, “Digital newcomers out to disrupt South African banking – Nasdaq” and the last “Prospective Study Demonstrates EndoPredict® Can Guide Chemotherapy Decision For Women with Early-Stage Breast Cancer – Nasdaq” with publication date: December 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.